Navigation Links
Cardiometabolic Health Congress Expert Faculty Evaluate the Clinical Implications of Newly FDA-Approved Treatment for Homozygous Familial Hypercholesterolemia

Boston, MA (PRWEB) January 08, 2013

The U.S. Food and Drug Administration (FDA) approved JUXTAPID™ (lomitapide), a new, first-in-class treatment option for clinical management of patients with homozygous familial hypercholesterolemia (HoFH) on December 28, 2012. The FDA decision prompted the Cardiometabolic Health Congress (CMHC) expert faculty to examine the implications this new treatment option may have on physician practice and patient care.

HoFH, an inherited genetic disorder caused by a mutation to the LDL receptor, is associated with early onset of atherosclerosis and premature cardiac death. Patients with HoFH tend to respond poorly to statin therapy because of low LDL receptor activity. For patients with HoFH who do not respond to statin therapy, LDL apheresis is indicated. This approach is expensive, invasive, and not universally available or effective alone – many patients do not achieve target LDL-C levels and as many as 30 percent of pediatric patients receiving long-term LDL apheresis progress to atherosclerotic disease of the coronary arteries and/or aorta.

Daniel Rader, MD, Cooper-McClure Professor of Medicine and Pharmacology and chief of the Division of Translational Medicine and Human Genetics in the Department of Medicine, the Perelman School of Medicine at the University of Pennsylvania, stated, “The magnitude of LDL-C and apoB reduction seen with lomitapide in patients with HoFH is substantially greater than that achieved with any other pharmacologic therapies in this disease and is expected to change the course of the disease and delay the onset and progression of atherosclerotic cardiovascular disease.”

For patients with HoFH, heart and vascular disease often develop in childhood, and the average age of death is approximately 30 years. For this reason, Robert H. Eckel, MD, co-chair of the CMHC and professor of medicine at the University of Colorado Anschutz Medical Campus remarked, “The FDA decision to approve lomitapide provides a new option for patients with HoFH, who so often develop extensive atherosclerotic cardiovascular disease as children, and remain inadequately treated.” Christie Ballantyne, MD, co-chair of the CMHC, chief, Section of Cardiovascular Research and Cardiology at Baylor College of Medicine and director of the Center for Cardiovascular Disease Prevention at Methodist DeBakey Heart and Vascular Center echoed a similar sentiment: “I am excited that we will have a new treatment option available for patients with HoFH.”

Sergio Fazio, MD, PhD, the Cornelius Vanderbilt Professor of Medicine and Pathology at Vanderbilt University School of Medicine in Nashville, Tenn., and chief of the Section of Cardiovascular Disease Prevention, cited the significance of the lomitapide approval: “This novel therapy is at the other end of the spectrum of cholesterol-lowering therapies – not a drug for everyone, like the statins, but an extreme intervention for extreme situations. Its mechanism of action is based on the inhibition of MTP, an intracellular protein that moves the lipid droplet to the forming lipoprotein in the liver and intestine. By targeting lipoprotein assembly, lomitapide has the power to reduce cholesterol irrespective of the type of mutation causing FH, since its effect is not based on up-regulation of the LDL receptor.”

Convening Oct. 2–5, 2013, in Boston, the CMHC is co-chaired by George L. Bakris, MD; Christie M. Ballantyne, MD; Robert H. Eckel, MD; and Jay S. Skyler, MD, MACP. The CMHC provides the most advanced-level cardiometabolic education encompassing a multitude of risk factors, including cardiovascular disease, obesity, type 2 diabetes, dyslipidemia, atherosclerosis, hypertension, thrombosis, acute coronary syndrome, chronic kidney disease and related comorbidities.

For more information, contact Dina Kouveliotes at info(at)cardiometabolichealth(dot)org or 877-571-4700 or visit


Dr. Christie Ballantyne – Consultant: Aegerion Pharmaceuticals

Dr. Sergio Fazio – Consultant: participated in an advisory meeting sponsored by Aegerion Pharmaceuticals

Dr. Daniel Rader – Ownership Interest/Shareholder: Aegerion Pharmaceuticals

Read the full story at

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Midwest Healthcare Startups Raise $996 Million in 2012
2. HealthEconomics.Com Appoints New Director of Information Technology and Operations
3. Join Cato BioVentures and Cancer Advances at Biotech Showcase 2013 & J.P. Morgan 31st Annual Healthcare Conference
4. BulletinHealthcare a TOP 10 “Most Innovative Company” of 2012 According to Pharma Marketing Publication PM360
5. First Maryland Hospital Offering 3D Mammograms? VA Maryland Health Care System
6. Opedix® Kinetic Health Gear Unveils New KNEE-Tec™ Knee Support Tights Shown to Reduce Quadriceps Muscle Fatigue and Knee Pain
7. The Medzilla Employment Report for December, 2012: Unemployment Drops to Lowest Rate in 4 Years; Experts Predict Unprecedented Growth in Healthcare IT
8. Life Solutions Advocates Announces New Partnerships in Health Promotion and Disease Prevention Initiative
9. Trending HealthEconomics.Com Pharma Pricing, Reimbursement, and Health Policy Stories Feature Rising Trend in Pharma Price Cuts to Secure Reimbursement
10. Insmed to Present at 31st Annual J.P. Morgan Healthcare Conference
11. Analysis of Venture Capital Investment Trends in the North American and European Healthcare Industry
Post Your Comments:
(Date:10/8/2015)... /PRNewswire/ - RepliCel Life Sciences Inc. (OTCQB: REPCF) (TSX.V: RP), ... development of autologous cell therapies, today announced its schedule of ... in the month of October: Stem Cell ... will be presenting at the annual Partnering Forum, part ... be held October 7-9 in La Jolla, ...
(Date:10/8/2015)... ... October 08, 2015 , ... Cystic fibrosis (CF) is ... (CFTR) gene and results in dysfunction of the lungs and the gastrointestinal (GI) ... This mucus is very difficult to clear, blocks the airways and the glands, ...
(Date:10/7/2015)...  ChromaDex Corp. (OTCQX: CDXC), an innovator of ... science-based solutions for dietary supplement, food and beverage, ... announced that the October 1 presentation from ... available for on-demand viewing at ...   --> LINK: ...
(Date:10/7/2015)... Md. , Oct. 7, 2015   Intrexon ... synthetic biology, today announced it will hold an Investor ... on the afternoon of Thursday, November 12, 2015. Intrexon,s ... and other members of the Company,s management team ... including a focus on strategic initiatives, product pipeline, and ...
Breaking Biology Technology:
... was at a security conference and stayed at a hotel, ... claimed that they had implemented it so only those on ... ,I do not purchase wireless Internet service when Im at ... the seminar hosts office. Out of curiosity, on my second ...
... Commerce has announced that it is producing the Wisconsin ... Thursday, September 25, from 8:30 a.m. to 3:45 p.m. ... , ,Wisconsins medical device and technology cluster is ... state, said Department of Commerce (Commerce) Secretary Cory L. ...
... all things e-commerce will speak to cutting-edge Madisonians Thursday evening ... Club Majestic, 115 King Street in downtown Madison. , ,Nationally ... about how e-commerce is coming out of the weeds after ... Some companies are finally learning how to please consumers and ...
Cached Biology Technology:
(Date:9/10/2015)... LONDON , Sept. 10, 2015 Report ... thus far not quite delivered upon previous expectations of ... might be the breakthrough year in which wearables begin ... been expected. One of the main reasons is the ... disrupt not only the SmartWatches market, but the overall ...
(Date:9/8/2015)... , Sept. 8, 2015   TREW Marketing ... new survey, Smart Marketing for Engineers TM : ... engineering professionals reveals insightful findings about engineers, preferences for ... of content engineers most value and trust, and where ... Marketers targeting technical audiences grapple with how to best ...
(Date:9/2/2015)... Biometric technology ... system which uses identical human characteristic such as ... and finger print. Increasing number of terror attacks ... which provides high level of security. Traditional security ... are vulnerable to attacks. Furthermore, Biometric technology uses ...
Breaking Biology News(10 mins):
... adults living closer to a fast food restaurant had a ... away from fast food, according to researchers at The University ... particularly strong among those with a lower income. ... of Public Health indicates higher BMI associates with residential ...
... relationship between the heritable risk for schizophrenia and low ... associated with cognitive impairments that may cause functional disability. ... to the risk for developing schizophrenia. For example, reduced ... Also, these deficits may be present in healthy relatives ...
... hematopoiesis at sites outside the bone marrow in ... (LMU) in Munich now show that a specific type ... blood cells. Balanced hematopoiesis is essential for the ... takes place mainly in the liver and the spleen. ...
Cached Biology News:
Sheep polyclonal to Melatonin ( Abpromise for all tested applications). Antigen: Melatonin Tg conjugate....
Goat polyclonal to DDDDK tag (FITC) ( Abpromise for all tested applications)....
Biology Products: